Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma

International Journal of Cancer

Volumn 110, Issue 3, 2004, Pages 452-458

  Li, Anna Aihua ^a,b   Ng, Emily ^c   Shi, Wei ^a,b   Lee, Andrew ^c   Chia, Marie ^a,b   Liu, Ta Jen ^d   Huang, Dolly ^e   O'Sullivan, Brian ^a,b   Gullane, Pat ^a,c   Liu, Fei Fei ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adenoviral vectors; Apoptosis; Nasopharyngeal cancer; p16; Senescence

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; FOLLOW UP; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; METHYLATION; MITOSIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SCID MOUSE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CARCINOMA; CELL AGING; CELL CYCLE; CELL SURVIVAL; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HERPESVIRUS 4, HUMAN; HUMANS; KINETICS; MICE; MICE, INBRED BALB C; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 2442545350     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20065     Document Type: Article

References (37)

1. Jeannel D BG, Huber A. Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis. Cancer Surv 1999;33:125-55.
2. Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev 1993;15:466-85.
3. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002;12:431-41.
4. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee, JC, Hjelm, NM, Johnson, PJ, and Huang, DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
5. Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, Wong, N, Choi, PH, Lee, JC, and Huang, DP. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 1999;82:498-503.
6. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:451-62.
7. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
8. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
9. Shim YH, Park HJ, Choi MS, Kim JS, Kim H, Kim JJ, Jang, JJ, and Yu, E. Hypermethylation of the p16 Gene and Lack of p16 Expression in Hepatoblastoma. Mod Pathol 2003;16:430-6.
10. Zhang L, Fang Y, Huang B, Hou J, Zhao M, Li H, Zeng, YX. Rapid tissue microarray assay of p16 protein expression for different stage nasopharyngeal carcinoma. Zhonghua Bing Li Xue Za Zhi 2002;31: 132-4.
11. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert, E, Day, RS, 3rd, Johnson, BE, and Skolnick, MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
12. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999;97:53-61.
13. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee, JC, and Huang, DP. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 1999;81: 1122-6.
14. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, and Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
15. Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O'Sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, Warde P, Irish J, et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003;9:2177-84.
16. Lee A LJ-H, Shi W, Li A, Ng E, Liu T-J, Klamut HJ, Liu FF. P16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol Cancer Ther 2003;2:961-9.
17. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, and Lee JC. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
18. Sizhong Z, Xiukung G, Yi Z. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 1983;31:587-90.
19. Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999;43:607-16.
20. Li JH, Li P, Klamut H, Liu FF. Cytotoxic-effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines. Clin Cancer Res 1997;3:507-14.
21. Li JH, Chia M, Shi W, Ngo D, Strathdee CA, Huang D, Klamut H, and Liu FF. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 2002;62:171-8.
22. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-93.
23. Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol 1995;46:187-216.
24. Lax SA, Chia MC, Busson P, Klamut HJ, Liu FF. Adenovirus-p53 gene therapy in nasopharyngeal carcinoma xenografts. In Medical biophysics. Toronto: University of Toronto, 1999.
25. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, and Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
26. Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ 2000; 11:373-84.
27. Wolf JK, Kim TE, Fightmaster D, Bodurka D, Gershenson DM, Mills G, Wharton J.T. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 1999;73:27-34.
28. Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001;7:1765-72.
29. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001;8:199-208.
30. Lo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995;55:2039-43.
31. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC, Huang DP. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996;56:2721-5.
32. Hakem R, Mak TW. Animal models of tumor-suppressor genes. Annu Rev Genet 2001;35:209-41.
33. Calbo J, Marotta M, Cascallo M, Roig JM, Gelpi JL, Fueyo J, Mazo A. Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 2001;8:740-50.
34. Steiner MS, Wang Y, Zhang Y, Zhang X, Lu Y. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 2000;19:1297-306.
35. Kawabe S, Roth JA, Wilson DR, Meyn RE. Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 2000;19:5359-66.
36. Li JH, Huang D, Sun BF, Zhang X, Middeldorp J, Klamut H, Liu FF. Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma. Int J Cancer 2000;87: 606-10.
37. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18:723-7.